England becomes first to offer belantamab mafodotin for multiple myeloma  

Around 1,500 people in England with multiple myeloma will benefit from belantamab mafodotin, used in combination with bortezomib and dexamethasone.

Advertisements



Latest Academic Articles

The latest academic articles from a wide range of themes such as energy, environment, health, agriculture, social sciences and technology plus more.

Open Access eBooks

The latest open access and free to distribute eBooks from key industry stakeholders covering health, energy, environment, plus more.

Horizon Europe

COP Climate Change

Special Reports